Comparative Pharmacology
Head-to-head clinical analysis: MOMETASONE FUROATE versus NATROBA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOMETASONE FUROATE versus NATROBA.
MOMETASONE FUROATE vs NATROBA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced arachidonic acid release, and decreased synthesis of prostaglandins and leukotrienes. It also suppresses cytokines, chemokines, and adhesion molecules involved in inflammation.
Natroba is a pediculicide that inhibits neuronal depolarization by binding to and blocking voltage-gated sodium channels in the nervous system of lice, leading to paralysis and death of the parasite.
Inhaled: 110-880 mcg twice daily; Intranasal: 2 sprays (50 mcg/spray) per nostril once daily; Topical: Apply thin film to affected area once daily.
Apply a single, 10-minute application of the lotion (0.5% w/w ivermectin) to dry hair and scalp in an amount sufficient to thoroughly coat the hair and scalp (up to 1 tube for adults); rinse off with water after 10 minutes.
None Documented
None Documented
The terminal elimination half-life is approximately 5.8 hours (range 4.5–7.5 hours) following intravenous administration; after intranasal or inhalation use, the effective half-life supporting once-daily dosing is derived from receptor binding and local tissue retention.
Terminal elimination half-life is approximately 10–12 hours in patients with normal hepatic function; prolonged in severe hepatic impairment.
Mometasone furoate is extensively metabolized in the liver; less than 1% of the dose is excreted unchanged in urine. The metabolites are primarily excreted in feces (~74%) via biliary elimination, with renal excretion accounting for approximately 8–10%.
Primarily fecal (approximately 90% of absorbed dose) with minor renal elimination (<10% as unchanged drug).
Category A/B
Category C
Topical / Inhaled Corticosteroid
Antiparasitic, Topical